Trevi Therapeutics (TRVI) PT Raised to $21 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TRVI Hot Sheet
Price: $13.99 +0.94%
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 13
Rating Summary:
12 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 27 | New: 13
Join SI Premium – FREE
Leerink Partners analyst Roanna Ruiz raised the price target on Trevi Therapeutics (NASDAQ: TRVI) to $21.00 (from $16.00) while maintaining a Outperform rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Double Downgrades Aardvark Therapeutics Inc (AARD) to Market Perform
- Datadog (DDOG) PT Lowered to $245 at Stifel
- Modine Manufacturing (MOD) PT Lowered to $215 at Oppenheimer
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
